Drug intelligence / Profile preview

istaroxime

Development stage: Phase 3
Lead developer: Windtree Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

Istaroxime is an investigational drug being developed for the treatment of acute decompensated heart failure. It acts as a positive inotropic agent by inhibiting sodium-potassium ATPase, which increases intracellular calcium levels, enhancing myocardial contractility. Additionally, it activates the sarcoplasmic reticulum calcium ATPase isoform 2a (SERCA2a), improving myocardial relaxation. Istaroxime is administered intravenously.

Other names: (E,Z)-Istaroxime3-((2-Aminoethoxy)imino)-5alpha-androstan-6,17-dione

Targets

SERCA2

Beyond the preview

Go deeper on istaroxime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on istaroxime.

Explore the full profile